Skip to main content
Premium Trial:

Request an Annual Quote

DNAnexus Closes $68M Financing Round

NEW YORK (GenomeWeb) – DNAnexus said today that it has closed a $68 million Series F round of venture funding. Existing investors GV — formerly Google Ventures — Foresite Capital, TPG Biotech, WuXi NextCode, and Claremont Creek Ventures participated, while Innovatus Capital Partners provided both debt and equity financing.

Mountain View, California-based DNAnexus said that the new capital will support deployment of DNAnexus Apollo, a recently released platform for multi-omics and clinical data science exploration, analysis, and discovery.

"The financing enables further development of our translational research solutions, as well as continued growth in genomics with cloud-based solutions for research, clinical diagnostics, and clinical trials," CEO Richard Daly said in a statement. "The next wave of biomedical insights will be derived from cross-institutional collaborations that generate massive volumes of clinical and multi-omics data," he predicted.

DNAnexus last announced new investment in January 2018, when it closed a $58 million Series E round of venture capital. With the additional $68 million, the company has now raised about $208 million since 2009.


The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.